Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors.

Iftehimul, M., Newman, R. H., Harrison, S. H., Jones, R. B., Muganda, P. M., Holloman, B. L., Hossain, M. T., Rorie, C. J., Thomas, M. D., Graves, J. L., Kaufman, H. L., & Saha, D. (2026). Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors.. Computational and Structural Biotechnology Journal, 31, 169-178.

Abstract

BACKGROUND: The triple-negative breast cancer (TNBC) microenvironment undergoes progressive reprogramming, transitioning from an early immune-active state to a late immune-suppressed state. While tumor cell plasticity has been extensively studied, the temporal molecular remodeling of T cells in vivo remains poorly defined.

RESULTS: Transcriptional analysis of T cells within 4T1 TNBC tumors, harvested at one-, three-, and six-weeks post-tumor implantation in the mammary fat pads of BALB/c mice, revealed a decline in transcriptomic signatures associated with T cells from 194 at one week to 156 at six weeks, with a significant late-stage loss or reduction of transcripts related to T cell receptors (TCR), natural killer T, and gamma delta T cells. Furthermore, changes in various temporal signature genes specific to T cell cytokines and transcription factors reflected temporal T cell polarization to CD4+ type 1 T helper and type 1 CD8+ cytotoxic T cell responses at one week, CD8+ cytotoxic follicular T cell skewing at three weeks, and interleukin 17/22 producing CD8+ T cell transition at six weeks. The antigen-presenting cell (APC) transcripts deteriorated at six weeks, characterized by reduced expression of co-stimulatory and APC genes. Despite an early dominance of M1-like macrophage genes (e.g., IL-12α/β), persistent expression of arginase 1 (ARG1) and other M2-associated genes indicated a stable tolerogenic niche.

CONCLUSIONS: The temporally coordinated immune shifts, such as progressive decline in transcripts associated with T cell functions, TCRs, APCs, and sustained macrophage-driven immunosuppression, suggest tumor-driven adaptation toward immune evasion and identify potential windows for stage-specific immunotherapeutic intervention.

Last updated on 04/01/2026
PubMed